• Palonosetron’s Role in Improving CINV Prevention Protocols

  2026-05-01

  Ruhlmann and Herrstedt’s review critically evaluates palonosetron hydrochloride for the prevention of chemotherapy-induced nausea and vomiting (CINV), highlighting its distinct pharmacologic properties and clinical benefits over previous 5-HT3 antagonists. Their synthesis of preclinical and clinical data informs evidence-based antiemetic selection, particularly in protocols involving agents such as dacarbazine.

• Novel 14-3-3 Binding Partners ATG9A and PTOV1 in Cancer Cont

  2026-05-01

  This study identifies ATG9A and PTOV1 as previously unrecognized binding partners of 14-3-3 proteins and elucidates their mechanistic roles in autophagy regulation and oncogenic stability, respectively. The findings highlight new regulatory mechanisms underlying cancer progression and open avenues for targeted therapeutic research.

• Doxorubicin Hydrochloride: Workflows and Cardiotoxicity Mode

  2026-04-30

  Doxorubicin hydrochloride (Adriamycin HCl) is indispensable for both cancer chemotherapy research and modeling drug-induced cardiotoxicity. This guide delivers actionable protocols, troubleshooting insights, and practical takeaways from the latest mechanistic studies, empowering researchers to maximize reproducibility and translational impact.

• Aclacinomycin A: Applied Protocols for DNA Damage and Apopto

  2026-04-30

  Aclacinomycin A (Aclarubicin) is a dual topoisomerase inhibitor with unique utility in dissecting DNA damage and apoptosis pathways. This article details optimized experimental workflows, highlights comparative advantages over classic anthracyclines, and translates recent mechanistic insights into actionable assay strategies.

• Ruxolitinib Disrupts Mitochondrial Dynamics in Anaplastic Th

  2026-04-29

  This study establishes that Ruxolitinib (INCB018424) induces apoptosis and GSDME-mediated pyroptosis in anaplastic thyroid carcinoma (ATC) cells by inhibiting DRP1-driven mitochondrial fission through JAK1/2-STAT3 pathway suppression. The findings highlight the therapeutic promise of JAK/STAT signaling pathway modulation in aggressive solid tumors with previously limited treatment options.

• Topotecan HCl: Mechanistic Precision and Translational Lever

  2026-04-29

  This thought-leadership article unites mechanistic insight and strategic guidance for translational researchers exploring DNA damage, topoisomerase 1 inhibition, and cancer model optimization with Topotecan HCl. Drawing on recent discoveries in DNA damage-induced neuronal vulnerability, the piece frames Topotecan HCl’s role not just as a potent antitumor agent but as a precision tool for dissecting apoptosis and therapy resistance—offering actionable protocol advice, clinical context, and a forward-looking perspective for oncology innovators.

• KPT330 Enhances CRISPR-Cas9 Precision via mRNA Nuclear Expor

  2026-04-28

  The referenced study demonstrates that the FDA-approved drug KPT330 improves the specificity of CRISPR-Cas9 genome and base editing by selectively inhibiting the nuclear export of Cas9 mRNA, offering a novel, indirect mechanism to mitigate off-target effects. This approach expands the genome editing toolbox and may inform safer, more controlled applications in mammalian systems.

• Batimastat (BB-94): Transforming Translational MMP Inhibitio

  2026-04-28

  This thought-leadership article provides translational researchers with a deep mechanistic understanding of matrix metalloproteinase (MMP) inhibition using Batimastat (BB-94), explores strategic considerations for experimental design, and highlights recent findings on the nuanced regulation of neurotrophic factors at the neuromuscular junction. By connecting emerging insights from basic neurobiology to cancer research, this article advances the conversation beyond standard product pages, outlining both the opportunities and limitations for cross-domain application.

• Lenalidomide (CC-5013): Applied Protocols & Innovation in My

  2026-04-27

  Harnessing Lenalidomide (CC-5013) as an immune system activation agent unlocks new experimental synergies in multiple myeloma research, especially when paired with epigenetic modulation. This guide delivers actionable workflows, advanced troubleshooting, and data-driven insights to help researchers maximize reproducibility and translational impact with APExBIO’s trusted reagent.

• Methyl-β-cyclodextrin: Technical Guidance for Membrane Studi

  2026-04-27

  Methyl-β-cyclodextrin facilitates the selective extraction of cholesterol and related lipids from cell membranes, supporting studies of membrane fluidity, lipid raft integrity, and cholesterol-dependent signaling pathways. It is intended strictly for research workflows and should not be applied in diagnostic or therapeutic settings. Adherence to storage, solubilization, and handling guidance is critical for experimental success.

• Miltefosine: Applied Protocols for PI3K/Akt Pathway and Neut

  2026-04-26

  Miltefosine, a unique dual-pathway modulator, enables advanced workflows in both cancer and hematology research. This guide translates cutting-edge findings—including Ras/MEK/ERK-driven neutrophil differentiation—into actionable experimental strategies, troubleshooting advice, and optimization tips for maximizing data quality.

• TPCA-1 (A4602): Reliable IKK-2 Inhibition for Cell Assays

  2026-04-25

  This article addresses key laboratory challenges in cell viability, proliferation, and cytotoxicity assays, demonstrating how TPCA-1 (SKU A4602) enables reproducible, data-driven NF-κB pathway inhibition. Drawing on scenario-based Q&A, validated protocols, and comparative vendor analysis, we show why TPCA-1 is a trusted IKK-2 inhibitor for inflammation research workflows.

• Annexin V in Immune Imbalance: Strategic Leverage for Transl

  2026-04-24

  This thought-leadership article explores the mechanistic basis and strategic application of human recombinant Annexin V as a phosphatidylserine binding protein in translational research. Drawing on recent immunological discoveries, including miR-519d-3p’s role in preeclampsia, it offers actionable protocol guidance and competitive landscape analysis for apoptosis assays in immune dysregulation. The discussion integrates references to APExBIO’s Annexin V, expanding beyond standard assay guides to chart new directions in cell death research and immune tolerance models.

• Catalpol’s Multifaceted Protection in Cardio-Cerebrovascular

  2026-04-24

  This review comprehensively evaluates catalpol, an iridoid glucoside, for its protective effects against cardio-cerebrovascular diseases (CVDs). The paper synthesizes recent mechanistic and preclinical findings, emphasizing catalpol’s antioxidant, anti-inflammatory, and antiapoptotic activities, and highlights the need for further translational and clinical research.

• TMRE Mitochondrial Membrane Potential Assay Kit: Precision &

  2026-04-23

  The TMRE mitochondrial Membrane Potential Assay Kit (APExBIO, K2233) enables high-throughput, quantitative analysis of mitochondrial health and apoptosis via a robust, fluorescence-based workflow. Leveraging the latest mechanistic insights into sodium-driven mitochondrial dysfunction, this kit empowers researchers to dissect energy metabolism and cell fate with unprecedented sensitivity and reliability.

15637 records 1/1043 page Next 12345 下5页 Last page